



ROTH Capital Partners



ROTH Capital Partners Acts as Co-Manager on \$47.4 Million Common Stock Offering for Clinical Data, Inc. (CLDA)

Client Information

Clinical Data develops first-in-class and best-in-category therapeutics. The Company is advancing its late-stage drug candidates for central nervous system disorders and cardiovascular diseases, to be followed by promising drug candidates in major therapeutic areas including oncology and inflammatory diseases. Clinical Data plans to differentiate its therapeutics by combining its drug development and biomarker expertise to develop products with enhanced efficacy and tolerability, improving patient health and reducing costs. (Source: Clinical Data, Inc.)

Transaction Information

On October 28, 2009 Clinical Data, Inc. (CLDA) announced an underwritten public offering of 2,750,000 shares of its common stock for a per share price of \$17.25. The offering of the shares was made pursuant to a registration statement previously filed with the Securities and Exchange Commission. ROTH Capital Partners acted as the co-manager for the offering. Clinical Data, Inc. has granted a 30-day over-allotment option for 412,500 shares at the public offering price.

ROTH Capital Partners

ROTH is a full service investment banking firm dedicated to advising public and private emerging growth companies. Headquartered in Newport Beach, California, ROTH offers a wide array of services to both corporate and institutional clients including: initial public offerings, follow-ons, mergers and acquisitions, SPACs, PIPEs, private placements, investment research and institutional sales and trading.

For recent news about ROTH and upcoming events please visit

ROTH Press Room

ROTH Upcoming Conferences & Events

\$47,400,000

CLINICAL DATA

FOLLOW-ON
CO-MANAGER

October 2009

For more information on how ROTH can help you, please contact:

Investment Banking

John Dalfonsi
Managing Director
310-445-5866
jdalfonsi@roth.com

Christopher Jennings
Managing Director
310-445-5865
cjennings@roth.com

Equity Capital Markets

Aaron Gurewitz
Head of Equity Capital Markets
949-720-5703
agurewitz@roth.com

Lou Ellis
Sr. Vice President
949-720-5739
lellis@roth.com

Nazan Akdeniz
Sr. Vice President
949-720-5740
nakdeniz@roth.com

The material, information and facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2009.